
Schizophrenia Treatment Approved in Europe
Otsuka Pharmaceutical Europe Ltd. and H. Lundbeck A/S announced that the European Commission (EC) has approved Rxulti® (brexpiprazole) for the treatment of schizophrenia in adolescents aged 13 years and older. Brexpiprazole was previously approved in …